The vaccine did not cause any serious side effects and elicited antibody and T-cell immune responses, as stated by to trial results produce in a Lancet medical journal.
An experimental COVID-19 vaccine, being developed by the University of Oxford, was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.
A vaccine, called AZD1222 and being developed by pharmaceutical company AstraZeneca and scientists at a Britain’s University of Oxford, did not prompt any serious side effects and elicited antibody and T-cell immune responses, in a opinion of to trial results published in a Lancet medical journal.
“We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period,” study lead author Andrew Pollard of the University of Oxford said.
AstraZeneca’s is among the leading vaccine candidates against a pandemic that has claimed more than 600,000 lives, alongside others in mid and late-stage trials.
These include shots being developed by China’s Sinovac Biotech, another from state-owned Chinese firm Sinopharm, and one from the U.S. biotech firm Moderna.
AstraZeneca has signed agreements with governments around the world to supply the vaccine should it prove effective and gain regulatory approval. The company has said it will not seek to profit from the vaccine during the pandemic.
Researchers said the vaccine caused minor side effects more frequently than a control group, but some of these could be reduced by taking paracetamol, with no serious adverse events from the vaccine.